Berger M. Choices in IgG replacement therapy for primary immune deficiency diseases: subcutaneous IgG vs. intravenous IgG and selecting an optimal dose. Curr Opin Allergy Clin Immunol. 2011;11(6):532-538.
Siegel J. IVIg medication safety: a stepwise guide to production selection and use. Pharm Pract News. Dec 2010.
Siegel J. Immune globulins: therapeutic, pharmaceutical, cost, and administration considerations. Pharm Pract News. Jan 2010.
GBS/CIDP Foundation International. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) 101. https://www.gbs-cidp.org/cidp/. Accessed June 20, 2022.
Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Advances. 2019;3(23):3829-3866.
Neunert C, Lim K, Crowther M, et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011;17(6):4190-4207.
Robak T, Salama A, Kovaleva L, et al. Efficacy and safety of Privigen®, a novel liquid intravenous immunoglobulin formulation in adolescent and adult patients with chronic immune thrombocytopenic purpura. Hematology. 2009;14(4):227-236.
Stein MR, Nelson RP, Church JA, et al. Safety and efficacy of Privigen, a novel 10% liquid immunoglobulin preparation for intravenous use, in patients with primary immunodeficiencies. J Clin Immunol. 2009;29(1):137-144.
Data on file. Available from CSL Behring as DOF PVG-003.
Cramer M, Frei R, Sebald A, Maeder M. Stability over 36 months of new liquid 10% polyclonial immunoglobulin product (IgPro10. Privigen®) stabilized with L-proline. Vox Sang. 2009;96(3):219-225.
Bolli R, Woodtli K, Bärtschi M, Höfferer L, Lerch P. L-Proline reduces IgG dimer content and enhances the stability of intravenous immunoglobulin (IVIG) solutions. Biological. 2010;38(1):150-157.
Hagan JB, Fasano MB, Spector S, et al. Efficacy and safety of new 20% immunoglobulin preparation for subcutaneous administration, IgPro20, in patients with primary immunodeficiency. J Clin Immunol. 2010;30(5):734-745.
Sun A, Teschner W, Yel L. Improving patient tolerability in immunoglobulin treatment: focus on stabilizer effects. Expert Rev Clin Immunol. 2013;9(6):577-587.
Simon HU, Späth PJ. IVIG mechanisms of action. Allergy. 2003;58(7):543-552.
Maddur MS, Lacroix-Desmazes S, Bayry J, Kaveri SV. Intravenous polyclonal immunoglobulin in autoimmune diseases: clinical indications and mechanisms of action. Drug Discov Today Ther Strateg Autoimmun. 2009;6(1):5-11.
Jacob S, Rajabally Y. Current proposed mechanism of action of intravenous immunoglobulins in inflammatory neuropathies. Curr Neuropharmacol. 2009;7(4):337-342.
Imbach P, Lazarus AH, Kühne T. Intravenous immunoglobulin induce potentially synergistic immunomodulations in autoimmune disorders. Vox Sang. 2009;98(3):385-394.
Centers for Disease Control and Prevention. National Center for Health Statistics--ICD-10-CM. https://icd10cmtool.cdc.gov. Accessed June 20, 2022.